数据链接：
官方服务：
资源简介：
Interactions with DAAs in the real life cohort.
应用场景：
创建时间：
2021-02-12
相关数据集
Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C
Abstract: Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) bocepre
DataCite Commons2021-03-25 更新60
Reasons for discontinuation of telaprevir and incidence of the most common AEs and Grade 3–4 AEs during the telaprevir phase in the intent-to-treat population.
* Includes six F0–F2 patients.† Listed are drug-related AEs that occurred in at least 5% of the overall population during the telaprevir phase.‡ Included in this category are all related events that w
Figshare2015-12-03 更新40
DataSheet_2_Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study.pdf
The aims of our study was compare adherence measured by the medical possession ratio (MPR), time until discontinuation and describe adverse events after adding a DPP-4i, SGLT-2i, or sulfonylureas (SU)
NIAID Data Ecosystem20
Data_Sheet_1_Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice.docx
BackgroundData related to adverse drug reactions (ADRs), specifically immune-related adverse events (irAEs), in long-term treatment with immunotherapy in real-world practice is scarce, as is general i
NIAID Data Ecosystem50
Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database
There is a lack of real-world studies on the safety of Ilaris in large populations. The purpose of this study was to investigate adverse events (AEs) associated with Ilaris using data from the FDA Adv
Figshare2025-02-22 更新20
